Cargando…

Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells

Cisplatin is one of the most common drugs used for treatment of solid tumors such as ovarian cancer. Unfortunately, the development of resistance against this cytotoxic agent limits its clinical use. Here we report that YSY01A, a novel proteasome inhibitor, is capable of suppressing survival of cisp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Wei, Zhou, Quan, Yuan, Xia, Ge, Ze-mei, Ran, Fu-xiang, Yang, Hua-yu, Qiang, Guang-liang, Li, Run-tao, Cui, Jing-rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911881/ https://www.ncbi.nlm.nih.gov/pubmed/27326257 http://dx.doi.org/10.7150/jca.14519

Ejemplares similares

Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo
por: Zhang, Mei, et al.
Publicado: (2015)

Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells
por: Huang, Wei, et al.
Publicado: (2017)

YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways
por: Xue, Bingjie, et al.
Publicado: (2015)

Potentiation of Cisplatin Cytotoxicity in Resistant Ovarian Cancer SKOV3/Cisplatin Cells by Quercetin Pre-Treatment
por: Hasan, Aseel Ali, et al.
Publicado: (2023)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells
por: XU, YE, et al.
Publicado: (2015)

Modulation of cisplatin cytotoxicity by sulphasalazine.
por: Awasthi, S., et al.
Publicado: (1994)

Proteasome Inhibitor MG132 Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells and Inhibits Tumor Growth
por: Sun, Farui, et al.
Publicado: (2018)

A simple beam position monitor using Y.S.I. precision thermistors
por: Clear, B P
Publicado: (1972)

Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines
por: Abdullah, Nada, et al.
Publicado: (2021)

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines
por: Engblom, P, et al.
Publicado: (1999)

Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro
por: Paucarmayta, Ana, et al.
Publicado: (2020)

Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast
por: Gatti, Laura, et al.
Publicado: (2011)

MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability
por: Clodfelter, Jill E., et al.
Publicado: (2005)

Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest
por: Koprinarova, Miglena, et al.
Publicado: (2010)

Co-Delivery of Curcumin and Cisplatin to Enhance Cytotoxicity of Cisplatin Using Lipid-Chitosan Hybrid Nanoparticles
por: Khan, Muhammad Muzamil, et al.
Publicado: (2020)

Regulation of Cisplatin Cytotoxicity by Cu Influx Transporters
por: Abada, Paolo, et al.
Publicado: (2010)

Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors
por: Crean-Tate, Katie K., et al.
Publicado: (2021)

Cisplatin induces stemness in ovarian cancer
por: Wiechert, Andrew, et al.
Publicado: (2016)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

The Nrf2/PGC1α Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer
por: Deng, Xinyue, et al.
Publicado: (2020)

Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity
por: Freeburg, Elizabeth M, et al.
Publicado: (2009)

Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines
por: Ayyagari, Vijayalakshmi N., et al.
Publicado: (2017)

H-Ferritin Affects Cisplatin-Induced Cytotoxicity in Ovarian Cancer Cells through the Modulation of ROS
por: Salatino, Alessandro, et al.
Publicado: (2019)

Cisplatin-induced renal toxicity in elderly people
por: Duan, ZhiYu, et al.
Publicado: (2020)

Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc
por: Zuo, Yufang, et al.
Publicado: (2018)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells
por: Chun, Jaemoo
Publicado: (2023)

Cisplatin cytotoxicity is dependent on mitochondrial respiration in Saccharomyces cerevisiae
por: Inapurapu, Santhi priya, et al.
Publicado: (2017)

Proteasome inhibitor MG132 enhances the sensitivity of human OSCC cells to cisplatin via a ROS/DNA damage/p53 axis
por: Zheng, Zheng, et al.
Publicado: (2023)

PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells
por: Ho, Winson S., et al.
Publicado: (2016)

Metabolic interaction between amino acid deprivation and cisplatin synergistically reduces phosphoribosyl-pyrophosphate and augments cisplatin cytotoxicity
por: Wahwah, Nisreen, et al.
Publicado: (2020)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
por: Gamarra-Luques, Carlos D, et al.
Publicado: (2014)

Renin-angiotensin system inhibitors combined with cisplatin exacerbate cisplatin-induced nephrotoxicity in mice
por: Tsuji, Takumi, et al.
Publicado: (2022)

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation
por: Zhao, Lili, et al.
Publicado: (2019)

Apoptosis Induction with Combined Use of Cisplatin and Fisetin in Cisplatin-Resistant Ovarian Cancer Cells (A2780)
por: Jafarzadeh, Samira, et al.
Publicado: (2021)

HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer
por: Dou, Zhiyuan, et al.
Publicado: (2022)

Synergistic Enhancement of Cisplatin Cytotoxicity by SN‐38, an Active Metabolite of CPT‐11, for Cisplatin‐resistant HeLa Cells
por: Minagawa, Yukihisa, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_lf30q7mdsh1hlh7lh4loor9u6s